Initiator Pharma ASOSTO:INIT -1.45%24 WACC % is 2.39% as of Jul. 09, 2026, which is 27% below its 10-year median of 3.28. GuruFocus rates OSTO:INIT with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Initiator Pharma AS ranks better than 91.03% on this metric.
As of today (2026-07-09), Initiator Pharma AS's weighted average cost of capital is 2.39%%. Initiator Pharma AS's ROIC % is -439.18% (calculated using TTM income statement data).
Initiator Pharma AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Initiator Pharma AS (OSTO:INIT) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Initiator Pharma AS's weighted average cost of capital is 2.39%%. Initiator Pharma AS's ROIC % is -439.18% (calculated using TTM income statement data).
Initiator Pharma AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Initiator Pharma AS WACC % Historical Data
* Premium members only.
The historical data trend for Initiator Pharma AS's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Initiator Pharma AS's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Initiator Pharma AS WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Initiator Pharma AS's WACC % distribution charts can be found below:
* The bar in red indicates where Initiator Pharma AS's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Initiator Pharma AS's market capitalization (E) is kr186.192 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Initiator Pharma AS's latest one-year quarterly average Book Value of Debt (D) is kr5.09 Mil.
a) weight of equity = E / (E + D) = 186.192 / (186.192 + 5.09) = 0.9734
b) weight of debt = D / (E + D) = 5.09 / (186.192 + 5.09) = 0.0266
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.888%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Initiator Pharma AS's beta is -0.0886.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.888% + -0.0886 * 6% = 2.3564%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Initiator Pharma AS's interest expense (positive number) was kr0.213 Mil. Its total Book Value of Debt (D) is kr5.09 Mil.
Cost of Debt = 0.213 / 5.09 = 4.1847%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -4.384 / -37.253 = 11.77%.
Initiator Pharma AS's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.9734
*
2.3564%
+
0.0266
*
4.1847%
*
(1 - 11.77%)
=
2.39%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Initiator Pharma AS (OSTO:INIT) has a WACC % of 2.39% as of Jul. 09, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Initiator Pharma AS and its competitors. This is 27% below median its historical median of 3.28. Over the past decade, Initiator Pharma AS's WACC % has ranged from 1.25 to 6.41. According to the industry distribution chart, Initiator Pharma AS ranks #127 out of 1416 companies in the Biotechnology industry, placing it in the top 9%.
Is Initiator Pharma AS's WACC % too high?
Initiator Pharma AS's current WACC % of 2.39% is 27% below median its 10-year median of 3.28. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 6.41. The Biotechnology industry median WACC % is 10.01. Initiator Pharma AS's value of 2.39% is 76.1% below this industry median. Based on the distribution chart, Initiator Pharma AS ranks #127 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Initiator Pharma AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Initiator Pharma AS's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Initiator Pharma AS ranks #127 out of 1416 companies for WACC %. This places Initiator Pharma AS in the top 9% of its industry — outperforming the majority of peers. The industry median WACC % is 10.01. Initiator Pharma AS's value of 2.39% is 76.1% below this benchmark. Historically, Initiator Pharma AS's own WACC % has ranged from 1.25 to 6.41 over the past decade. While the company's 10-year median is 3.28 vs. the industry median of 10.01, Initiator Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.01, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Initiator Pharma AS's current WACC % of 2.39% is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Initiator Pharma AS and its competitors. For the Biotechnology industry, the median WACC % is 10.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Initiator Pharma AS's current WACC % is 2.39%, which is 27% below median its own 10-year median of 3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Initiator Pharma AS stock overvalued right now?
Initiator Pharma AS (OSTO:INIT) has a current WACC % of 2.39%. The current WACC % is 2.39%, which is 27% below median its 10-year median of 3.28 and 76.1% below the Biotechnology industry median of 10.01. Initiator Pharma AS's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Initiator Pharma AS (OSTO:INIT), the current WACC % is 2.39% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Initiator Pharma AS is a Danish clinical-stage life science company developing drugs that target key unmet medical needs within the central and peripheral nervous system. Its pipeline consists of three clinical programs: IP2018 and pudafensine for the treatment of erectile dysfunction of psychogenic and organic origin, respectively.
24GF Score
Get the complete analysis for OSTO:INIT
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:INIT has been successfully added to your 
